They call to include Pharmacogenetics and Pharmacogenomics in the portfolio of services of the SNS.

DIARIOFARMA |   03.11.2020 - 13:47


The Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF) has published a position, together with the European Society for Pharmacogenetics and Personalized Therapy (ESPT), on the need for the implementation of Pharmacogenetics and Pharmacogenomics in the portfolio of basic services of the National System of Health (SNS), through the Personalized Medicine Strategy, thus complying with the conclusions of the presentation on genomics approved in the Senate.

They recall that currently "there is already a large number of approved drugs with pharmacogenetic recommendations of clinical utility", established by the drug agencies of Spain, Europe and the United States (Aemps, EMA and FDA, respectively), the international pharmacogenetics consortiums (CPIC, DPWG, RNPGx).

The Society indicates that "current scientific tools and knowledge already allow anticipating and knowing how certain genetic variants will influence the response of each individual to various treatments." Now the only thing missing, they think, is that the advances made in these disciplines be taken into account and incorporated into the Spanish Strategy for Personalized Medicine (MP).

Specifically, they refer to its usefulness to avoid adverse reactions to medications and failures in the expected response. They claim that many of them "are preventable and avoidable by incorporating pharmacogenetics into the Basic Portfolio of Services of the National Health System." "Only in this way will we be able to practice a more precise, more personalized, efficient and sustainable medicine, issues that are of special relevance for the sustainability of public health services", they say.

To carry out this transfer of knowledge into practice, the SEFF places itself "at the service" of the authorities, as indicated by its president, Adrián Llerena, who directs the University Institute for Biosanitary Research of Extremadura (INUBE) and the MedeA project of the Extremadura Health Service. This society brings together specialists from different scientific disciplines (Clinical Pharmacology, Hospital Pharmacy, Genetics, Biology, etc.), with experience in genetic variability in the response to pharmacological treatments in public hospitals and research centers throughout the country.

link to the news: